期刊文献+

96例胃肠道间质瘤临床诊治分析 被引量:25

Diagnosis and treatment of gastrointestinal stromal tumors:a study of 96 patients
原文传递
导出
摘要 目的 探讨胃肠道间质瘤的病理诊断、外科治疗及预后相关因素。方法 回顾分析 96例经手术治疗的胃肠道间质瘤患者的临床病理资料 ;免疫组织化学方法检测CD117、CD34、平滑肌肌动蛋白 (SMA)和S 10 0的表达情况。结果 免疫组织化学阳性表达率CD117为 79.2 % (76 / 96 )、CD34为 5 8.3% (5 6 / 96 )、SMA为 35 .4 % (34/ 96 )、S 10 0为 9.4 % (9/ 96 )。良性 2 3例 ,恶性 73例。恶性组病例中 ,首次手术中切除大网膜 39例 ,未切除大网膜 34例 ,转移复发率分别为 5 .1%和 2 6 .5 % (P <0 .0 5 ) ;手术切除肠管断端距肿瘤 >5cm 4 6例 ,≤ 5cm 2 7例 ,转移复发率分别为 6 .5 %和 2 9.6 % (P <0 .0 5 )。良、恶性胃肠道间质瘤 5年生存率分别为 91.5 %和 5 7.3%。结论 CD117及CD34等免疫标记物配合使用可以提高胃肠道间质瘤的病理诊断准确率。采用合理的首次手术治疗及大网膜预防性切除可减少胃肠道间质瘤的复发。 Objective To investigate the pathological diagnosis,surgical treatm ent and prognostic factors of gastrointestinal stromal tumors (GISTs). Methods The clinicopathological data of operated 96 patients with GISTs were analyzed r etrospectively. Expression of CD117,CD34,SMA and S-100 was determined by immu nohistochemical methods. Results Expression of CD117,CD34,SMA and S-100 was 7 9.2%(76/96),58.3%(56/96),35.4%(34/96) and 9.4%(9/96). Benign tumor 23 a n d malignant 73. Of the malignant,the omentum was resected in 39 and the rest re mained,of which the recurrent and metastatic rates were 5.1% and 26.5% ( P <0.0 5). The safety margin between the normal intestine and tumor was >5 cm in 46 pat i ents;while in the other 27 patients,it was <5 cm. The recurrent and metastatic rates were 6.5% and 29.6%( P <0.05),respectively. The 5-year survival r ates of benign and malignant GISTs were 91.5% and 57.3% ( P <0.05). Conclusion The appl ication of immunohistochemical markers CD117 and CD34 are supplementary to pat hol ogical diagnosis. The adapting of rational primary treatment,including complete tumor resection and prophylactic omentectomy,is able to reduce the recurrence of GISTs.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2004年第7期437-439,共3页 Chinese Journal of Oncology
关键词 胃肠道间质瘤 免疫组织化学 CD117 CD34 GISTS 肿瘤 Gastrointestinal neoplasms Stromal tumors Tumor recurrence CD117 CD34
  • 相关文献

参考文献9

  • 1Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol, 1999,23:82-87. 被引量:1
  • 2DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 2000,231:51-58. 被引量:2
  • 3Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 2001,438:1-12. 被引量:2
  • 4Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002,33:459-465. 被引量:2
  • 5Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol, 1998,152:1259-1269. 被引量:1
  • 6Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res, 1999,59:4297-4300. 被引量:2
  • 7Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer, 2002,38 Suppl 5:S52-S59. 被引量:2
  • 8Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg, 1992,215:68-77. 被引量:2
  • 9Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002,347:472-480. 被引量:2

共引文献1

同被引文献196

引证文献25

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部